Rametrix® Technology, Inc. has the ability to detect, stage and monitor Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD); distinguish between Diabetic and Non-diabetic Kidney Disease; detect, stage and monitor Bladder Cancer and detect, stage and monitor Long COVID.
Since 2016, I am involved in the Raman spectroscopic evaluation of the urine in the early diagnosis and screening of bladder cancer (In collaboration with Dr. John Robertson of the Virginia Tech). This is fascinating area of the study for me, because of my long-standing interest in the management of the bladder cancer, and that brought me to the collaboration with Rametrix® Technology, Inc. The ability of this methodology to evaluate the urine and able to establish urine profile for the patients with bladder cancer, other urological problems and healthy individuals, which was demonstrated in our preliminary studies, was very encouraging. The assessment by the Raman spectroscopy of the whole urine profile is very interesting, since this methodology is not relied on only a single, or several molecules in the urine to establish the diagnosis, but evaluates all components of the urine. Our hope is that Rametrix® Technology, Inc. technology, which is easy to administer and interpret, can be used in the early detection, as well as monitoring of the bladder cancer, which should improve treatment efficacy and survival of the patients with bladder cancer.
Another possible use of Rametrix® Technology, Inc. technology, which is also very interesting to me, is the possibility to identify special molecules associated with bladder cancer (since the contents of the whole urine could be evaluated and profiled!), and use them as potential targets in the cell-based immunotherapies of the bladder cancer. Considering my experience in general immunology, as well as cell-based immunotherapies of urological malignancies, our collaboration could become even more productive.
WE ARE Rametrix® Technology, Inc.
Every molecular fingerprint matters!